Windtree reports positive Phase 2b study on heart failure therapy
WARRINGTON, Pa. - Windtree Therapeutics, Inc. (NASDAQ:WINT), a biotechnology firm specializing in the development of therapies for critical diseases and currently valued at $1.44 million market ...
Medscape2d
Cardiogenic Shock
Cardiogenic shock is the leading cause of mortality in ... Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report ...
EurekAlert!3y
SCAI Stages of Cardiogenic Shock (IMAGE)
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
Too Old to Operate6d
Corticosteroid Administration and Mortality in Cardiogenic Shock
The following is a summary of “Corticosteroids in Cardiogenic Shock: A Retrospective Analysis of the Medical Information Mart ...
MyChesCo on MSN5mon
Windtree Therapeutics Reports Second-Quarter Financial Results and Key Business Updates
we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study as well as provide guidance on our ...
Too Old to Operate13d
Therapies and Mortality in Heart Failure Cardiogenic Shock
The following is a summary of “Patient Characteristics, Management and Long-term Outcomes of Patients with Cardiogenic Shock ...
Healio2y
Cardiogenic Shock
Cardiogenic shock occurs when the heart is not able to pump enough blood to generate adequate cardiac output to maintain normal blood pressure. This frequently occurs in the setting of a large ...